Guillain-Barre Syndrome, Antiphospholipid Syndrome and Lupus Nephritis as Initial Manifestation of Systemic Lupus Erythematosus

2012 ◽  
Vol 19 (5) ◽  
pp. 274 ◽  
Author(s):  
Ju-Yang Jung ◽  
Hyoun-Ah Kim ◽  
In-Soo Joo ◽  
Je-Hwan Won ◽  
Bo-Ram Koh ◽  
...  
2021 ◽  
pp. practneurol-2020-002849
Author(s):  
Paul Christopher Kopanidis ◽  
Alisa Kane ◽  
Minh Anh Nguyen ◽  
Romesh Markus

A 37-year-old woman developed progressive symmetrical weakness with areflexia, consistent with Guillain-Barré syndrome. After initially briefly responding to intravenous immunoglobulin, her weakness progressed markedly. Further investigation identified a new diagnosis of systemic lupus erythematosus with lupus nephritis. Following additional plasma exchange and corticosteroids, the lupus activity remitted and she made a complete neurological recovery.


2019 ◽  
Vol 12 (1) ◽  
pp. bcr-2018-226634 ◽  
Author(s):  
Eric Anthony Coomes ◽  
Hourmazd Haghbayan ◽  
Jenna Spring ◽  
Sangeeta Mehta

A 45-year-old man with a history of systemic lupus erythematosus presented with progressive weakness and areflexia. Electromyogram revealed reduced motor and sensory amplitudes without demyelinating features. He was clinically diagnosed with the acute motor and sensory axonal neuropathy variant of Guillain-Barré syndrome. Despite intravenous immunoglobulin therapy, he deteriorated with loss of all voluntary motor function and cranial nerve reflexes. Concomitant investigations revealed class V lupus nephritis. Therapy was initiated with plasma exchange, glucocorticoids and further immunosuppression, with gradual neurological recovery. We present the first documented case of fulminant Guillain-Barré syndrome as a neuropsychiatric manifestation of systemic lupus erythematosus, highlighting how immune-mediated polyneuropathy via diffuse deafferentation may mimic the outward appearance of brain death. While glucocorticoids are not indicated in idiopathic Guillain-Barré, when this neurological disorder is a consequence of systemic lupus erythematosus, immunomodulatory treatment should be initiated to prevent neurological deterioration.


Rheumatology ◽  
1989 ◽  
Vol 28 (5) ◽  
pp. 440-442 ◽  
Author(s):  
K. RAY CHAUDHURI ◽  
I. K. TAYLOR ◽  
R. M. NIVEN ◽  
R. J. ABBOTT

2021 ◽  
Author(s):  
Gustavo Roberto Lourenço ◽  
Danielly Dantas Pimentel ◽  
Gizelle Gouvea Rezende ◽  
Iane Tamara Dondé ◽  
Taisa Morete da Silva ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document